STOCK TITAN

CBD of Denver Inc. Announces Annual Disclosure and Filing of Financial Statements

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary

CBD of Denver, Inc. (CBDD) announced the filing of its financial results for 2023, showcasing significant improvements in total current assets, gross profit, and net income. The company's strategic efforts to enhance operational efficiency and cost management have led to positive financial outcomes. Accounts payable also decreased notably, reflecting the company's commitment to financial stability.

Positive
  • Total Current Assets increased to $117,218 in 2023 from $28,043 in 2022, strengthening the company's balance sheet.

  • Gross Profit for 2023 was $595,417, a substantial recovery from a gross loss of $(284,734) in 2022, attributed to increased sales and reduced Cost of Goods Sold.

  • Net Income Before Provision for Income Tax improved to a loss of $(377,729) in 2023 from $(3,257,710) in 2022, showcasing the company's focus on operational efficiency and cost management.

  • Accounts Payable decreased significantly to $297,164 in 2023 from $961,651 in 2022, indicating a positive trend in financial stability.

Negative
  • None.

Denver, Colorado--(Newsfile Corp. - May 2, 2024) - CBD of Denver, Inc. (OTC Pink: CBDD) has filed its financial results for the year ended December 31, 2023. The results highlight significant financial improvements and strategic achievements.

Financial Highlights:

Total Current Assets increased to $117,218 in 2023, up from $28,043 in 2022, marking significant progress in strengthening the company's balance sheet.

Gross Profit for 2023 was $595,417, a significant recovery from a gross loss of $(284,734) in 2022, due to a 27% increase in sales and reduction in Cost of Goods Sold, reflecting improved operational efficiency and product demand.

Net Income Before Provision for Income Tax showed improvement with a loss of $(377,729) in 2023, compared to a loss of $(3,257,710) in 2022. This underscores the company's efforts to enhance operational efficiency and improve cost management. Strategies include adopting a lean approach to minimize fixed expenses to the absolute bare minimum and managing variable expenses prudently, all while aiming to boost top-line growth.

Operational Highlights:

Net Income from Operations showed improvement with a reduced loss in 2023 compared to 2022. These figures represent diligent efforts in operational adjustments and cost management.

Accounts Payable decreased significantly to $297,164 in 2023, down from $961,651 in 2022.

"It is with great pride that I report on the robust financial performance and strategic achievements of CBD of Denver for the year 2023," said Axel Reinke, CEO of CBD of Denver. "The transformation from substantial losses in the previous year reflects the determination and adaptability of our team. We remain dedicated to driving growth, maximizing shareholder value, and spearheading innovation in our industry."

Three notes (Capitoline Ventures II LLC, Goldberg AG, and Pascal Siegenthaler) have been extended for an additional two years. These notes are held by friendly debt holders who have, and the company believes, will continue, to support CBD of Denver Inc.

About CBD of Denver, Inc. (BERLINER INNOVATION)

CBD of Denver, Inc. is focused on acquiring profitable assets at attractive valuations to create value for shareholders. The company's team is dedicated to sourcing high-margin, innovative products that align with its values. The Company is offering a number of innovative consumer products through Libra 9 GmbH, such as the Magic Lappen and the BerlinR13 Anti-Slip solution.

Follow Magic Lappen on Twitter, Instagram, Facebook and TikTok for more information and updates.

Follow The Magic Lappen on Instagram: @themagiclappen

Shop on our website: https://www.the-magic-lappen.com/

Visit the CBDD/ Berliner Innovation: www.berlinerinnovation.de

See our innovative Anti-Slip product: www.berlinr13.de

For questions, please contact us at: investors@libra9.de

About LUXORA Inc.

LUXORA Inc. is a trailblazing entity in the European cannabis industry, with offices spanning the USA and Europe. Our core expertise revolves around unlocking the potential of the legalized cannabis market, offering infrastructure solutions and consulting tailored to the dynamic needs of this rapidly expanding sector. With a profound understanding of the opportunities and challenges brought forth by legalization, our experienced team is dedicated to pioneering the future of the legal cannabis market in Europe. Our offerings range from consulting and market research to product development and distribution solutions, aimed at simplifying the path to legalization for our esteemed clients.

For inquiries, please contact Investor Relations: investors@luxora-holding.com.

For more information, please visit: www.luxora-holding.com.

Follow Us: Twitter | Instagram.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/207767

FAQ

What financial results did CBD of Denver announce for the year ended December 31, 2023?

CBD of Denver announced financial results for the year ended December 31, 2023, showcasing improvements in total current assets, gross profit, and net income.

Who is the CEO of CBD of Denver?

Axel Reinke is the CEO of CBD of Denver.

What is the stock symbol of CBD of Denver?

CBDD is the stock symbol of CBD of Denver.

What notable achievements were highlighted in the financial results?

The financial results highlighted significant improvements in total current assets, gross profit, and net income for CBD of Denver.

What strategic efforts led to positive financial outcomes for CBD of Denver?

CBD of Denver's strategic efforts to enhance operational efficiency and cost management resulted in positive financial outcomes.

How did the company manage its accounts payable?

CBD of Denver managed to decrease its accounts payable significantly from $961,651 in 2022 to $297,164 in 2023, showcasing a commitment to financial stability.

CBD OF DENVER INC

OTC:CBDD

CBDD Rankings

CBDD Latest News

CBDD Stock Data

2.27M
7.55B
0%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Centennial